BioSpecifics Technologies Corp. (NASDAQ:BSTC) Given Consensus Recommendation of “Strong Buy” by Analysts

Shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus price objective of $90.00 for the company and are forecasting that the company will post $0.75 earnings per share for the current quarter, according to Zacks. Zacks has also assigned BioSpecifics Technologies an industry rank of 60 out of 256 based on the ratings given to its competitors.

BSTC has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of BioSpecifics Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price (up previously from $85.00) on shares of BioSpecifics Technologies in a report on Monday, August 12th. BidaskClub raised shares of BioSpecifics Technologies from a “sell” rating to a “hold” rating in a report on Saturday, September 14th. Finally, ValuEngine downgraded shares of BioSpecifics Technologies from a “hold” rating to a “sell” rating in a report on Thursday, August 1st.

Shares of BSTC stock traded down $0.31 during midday trading on Friday, hitting $58.15. 26,314 shares of the company were exchanged, compared to its average volume of 46,387. The firm has a market capitalization of $426.17 million, a P/E ratio of 21.30 and a beta of 1.17. The firm’s 50 day moving average price is $56.73 and its two-hundred day moving average price is $61.68. BioSpecifics Technologies has a 52 week low of $52.03 and a 52 week high of $73.31.

BioSpecifics Technologies (NASDAQ:BSTC) last announced its earnings results on Friday, August 9th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.72 by $0.15. The business had revenue of $8.85 million during the quarter, compared to the consensus estimate of $8.98 million. BioSpecifics Technologies had a net margin of 63.06% and a return on equity of 21.97%. As a group, equities research analysts predict that BioSpecifics Technologies will post 3.17 earnings per share for the current fiscal year.

In other BioSpecifics Technologies news, Director Toby Wegman sold 1,100 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $55.23, for a total value of $60,753.00. Following the completion of the sale, the director now owns 1,890 shares of the company’s stock, valued at approximately $104,384.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 16.39% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Advisor Group Inc. boosted its holdings in BioSpecifics Technologies by 94.2% in the 2nd quarter. Advisor Group Inc. now owns 734 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 356 shares during the period. Advantage Investment Management LLC raised its position in shares of BioSpecifics Technologies by 40.9% in the 2nd quarter. Advantage Investment Management LLC now owns 957 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 278 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in shares of BioSpecifics Technologies by 60,150.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,205 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 1,203 shares in the last quarter. Shaker Investments LLC OH acquired a new position in shares of BioSpecifics Technologies in the 2nd quarter valued at approximately $205,000. Finally, Victory Capital Management Inc. acquired a new position in shares of BioSpecifics Technologies in the 1st quarter valued at approximately $248,000. 59.16% of the stock is owned by hedge funds and other institutional investors.

About BioSpecifics Technologies

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

Featured Article: Forex

Get a free copy of the Zacks research report on BioSpecifics Technologies (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.